Chartwell Investment Partners LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 29,308 shares of the biotechnology company’s stock, valued at approximately $3,546,000. Chartwell Investment Partners LLC owned approximately 0.07% of United Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently made changes to their positions in UTHR. CWM LLC boosted its holdings in United Therapeutics by 696.2% in the 2nd quarter. CWM LLC now owns 207 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 181 shares during the period. Altshuler Shaham Ltd purchased a new position in shares of United Therapeutics in the first quarter valued at $28,000. Banque Cantonale Vaudoise acquired a new stake in United Therapeutics during the 2nd quarter valued at $69,000. First Mercantile Trust Co. purchased a new stake in United Therapeutics during the 1st quarter worth $72,000. Finally, Parallel Advisors LLC lifted its holdings in United Therapeutics by 113.2% in the 2nd quarter. Parallel Advisors LLC now owns 646 shares of the biotechnology company’s stock worth $78,000 after buying an additional 343 shares in the last quarter. Institutional investors and hedge funds own 97.99% of the company’s stock.
Shares of NASDAQ:UTHR opened at $111.47 on Friday. The company’s fifty day moving average is $117.48 and its two-hundred day moving average is $106.45. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.46 and a current ratio of 7.43. United Therapeutics Co. has a 1-year low of $75.58 and a 1-year high of $127.79. The stock has a market capitalization of $4.91 billion, a price-to-earnings ratio of 11.44 and a beta of 0.86.
United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $2.41 earnings per share for the quarter, hitting the consensus estimate of $2.41. United Therapeutics had a net margin of 30.04% and a return on equity of 14.90%. The firm had revenue of $362.00 million for the quarter, compared to analyst estimates of $339.97 million. During the same quarter in the prior year, the business earned $3.63 earnings per share. United Therapeutics’s quarterly revenue was down 3.1% on a year-over-year basis. Sell-side analysts expect that United Therapeutics Co. will post 10.48 EPS for the current fiscal year.
Several analysts have recently weighed in on the company. BidaskClub downgraded United Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 15th. Cowen restated a “buy” rating and set a $145.00 price objective on shares of United Therapeutics in a report on Friday, June 12th. Wedbush reaffirmed a “buy” rating and issued a $244.00 target price (up from $243.00) on shares of United Therapeutics in a research report on Wednesday. HC Wainwright raised their price target on shares of United Therapeutics from $85.00 to $125.00 and gave the stock a “neutral” rating in a research report on Thursday, June 25th. Finally, Oppenheimer upped their price target on shares of United Therapeutics from $155.00 to $165.00 and gave the company an “outperform” rating in a report on Thursday. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. United Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $141.67.
In related news, Director Judy D. Olian sold 4,510 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $124.96, for a total value of $563,569.60. Following the sale, the director now owns 3,490 shares of the company’s stock, valued at approximately $436,110.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 10,000 shares of United Therapeutics stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $115.90, for a total transaction of $1,159,000.00. Following the completion of the sale, the chief executive officer now owns 10,140 shares in the company, valued at $1,175,226. The disclosure for this sale can be found here. In the last three months, insiders sold 242,210 shares of company stock worth $28,840,232. Company insiders own 10.90% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Read More: Book Value Per Share in Stock Trading
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.